4.8 Article

Myc overexpression brings out unexpected antiapoptotic effects of miR-34a

Journal

ONCOGENE
Volume 30, Issue 22, Pages 2587-2594

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.634

Keywords

microRNA; Myc; p53

Funding

  1. US National Institutes of Health [CA 122334]
  2. Children's Hospital of Philadelphia
  3. NIH [R01CA098172-07, R21CA152786-01, R01CA090465-08]

Ask authors/readers for more resources

Downregulation of microRNA-34a by Myc is known to be essential for tumorigenesis and improve tumor-cell survival. Conversely, upregulation of miR-34a by p53 is thought to enhance its acetylation and activity and contribute to the pro-apoptotic effects of this tumor suppressor. We sought to determine whether restoration of miR-34a levels in B-lymphoid cells with Myc overexpression would aid therapeutic apoptosis. Unexpectedly, delivery of miR-34a, which doesn't target p53 directly, severely compromised steady-state p53 levels. This effect was preceded and mediated by direct targeting of Myc, which sustained p53 protein levels via the Arf-Hdm2 pathway. As a result, in the presence of Myc, miR-34a inhibited p53-dependent bortezomib-induced apoptosis as efficiently as anti-p53 small interfering RNA. Conversely, inhibition of miR-34a using antisense RNA sensitized lymphoma cells to therapeutic apoptosis. Thus, in tumors with deregulated Myc expression, miR-34a confers drug resistance and could be considered a therapeutic target. Oncogene (2011) 30, 2587-2594; doi:10.1038/onc.2010.634; published online 7 February 2011

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available